Accumulating evidence supports the idea that pathogenic protein aggregates associated with neurodegenerative diseases spread between cells with prion-like properties. Here, we describe a method that enables visualization of cell-to-cell spreading of prion-like aggregates in the model organism, Drosophila melanogaster.
Protein aggregation is a central feature of most neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). Protein aggregates are closely associated with neuropathology in these diseases, although the exact mechanism by which aberrant protein aggregation disrupts normal cellular homeostasis is not known. Emerging data provide strong support for the hypothesis that pathogenic aggregates in AD, PD, HD, and ALS have many similarities to prions, which are protein-only infectious agents responsible for the transmissible spongiform encephalopathies. Prions self-replicate by templating the conversion of natively-folded versions of the same protein, causing spread of the aggregation phenotype. How prions and prion-like proteins in AD, PD, HD, and ALS move from one cell to another is currently an area of intense investigation. Here, a Drosophila melanogaster model that permits monitoring of prion-like, cell-to-cell transmission of mutant huntingtin (Htt) aggregates associated with HD is described. This model takes advantage of powerful tools for manipulating transgene expression in many different Drosophila tissues and utilizes a fluorescently-tagged cytoplasmic protein to directly report prion-like transfer of mutant Htt aggregates. Importantly, the approach we describe here can be used to identify novel genes and pathways that mediate spreading of protein aggregates between diverse cell types in vivo. Information gained from these studies will expand the limited understanding of the pathogenic mechanisms that underlie neurodegenerative diseases and reveal new opportunities for therapeutic intervention.
The prion hypothesis states that the infectious agent responsible for the transmissible spongiform encephalopathies (e.g., Creutzfeldt-Jakob disease in humans, scrapie in sheep, chronic wasting disease in deer and elk, and "mad cow disease" in cattle) is solely composed of protein and devoid of nucleic acids1. In prion diseases, the cellular prion protein (PrPC) assumes a non-native, stable fold (PrPSc) that is highly beta sheet-rich and can self-propagate by converting and recruiting monomeric PrPC molecules into stable amyloid aggregates. PrPSc aggregates use this self-replicating mechanism to spread between different cells in an organism and even between individual organisms2.
Protein misfolding and aggregation is also a central feature of most neurodegenerative diseases (Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS))3. Formation of intra- or extra-cellular aggregated protein assemblies in these diseases is closely associated with cytotoxicity4 and progresses along highly reproducible and disease-specific paths through the brain over time5,6. These patterns of spread suggest that pathogenic aggregates associated with these disorders have prion-like properties. Strong support now exists for prion-like transmission of aggregates associated with AD, PD, HD, and ALS – they spread from cell-to-cell and template the conformational change of monomeric forms of the same protein in previously unaffected cells7,8.
The majority of studies investigating prion-like spread of protein aggregates to date have been performed using mammalian cell culture models, where aggregates transfer into the cytoplasm of naïve cells from the extracellular space or from another cell's cytoplasm9,10,11,12,13,14,15, or by injecting aggregate-containing material into mouse brains and monitoring aggregate appearance outside of the injection site16,17,18,19,20,21,22,23. More recently, transgenic animals have been used to demonstrate that intracellular aggregates spread to other cells within intact brains24,25,26,27,28,29,30. Here, we describe a method for direct visualization of aggregate transfer between individual cells in the intact brain of Drosophila melanogaster. Drosophila models of HD/polyglutamine (polyQ) diseases were first developed nearly two decades ago31,32 and have provided many invaluable insights into the pathogenic mechanisms that underlie these disorders33. HD is an inherited neurodegenerative disorder caused by an autosomal dominant mutation in the gene that codes for the protein huntingtin (Htt)34. This mutation results in expansion of a polyQ stretch near Htt's N-terminus beyond a pathogenic threshold of ~ 37 glutamines, causing the protein to misfold and aggregate35,36. Wild-type Htt proteins containing <37 glutamines in this stretch achieve their native fold, but can be induced to aggregate upon direct physical contact with a Htt aggregate "seed"12,27,37. We exploit this homotypic, nucleated aggregation of wild-type Htt as a readout for prion-like transfer and cytoplasmic entry of mutant Htt aggregates originating in other cells.
Determining the mechanisms by which prion-like aggregates travel between cells can lead to the identification of novel therapeutic targets for incurable neurodegenerative diseases. We take advantage of the rapid life cycle, ease of use, and genetic tractability of Drosophila melanogaster to define molecular mechanisms for cell-to-cell spread of mutant Htt aggregates. Our experimental strategy employs two binary expression systems available in Drosophila, the well-established Gal4-specific upstream activating sequence (Gal4-UAS) system38 and the recently-developed QF-QUAS system39. Coupling these two independent systems allows restricting expression of mutant and wild-type Htt transgenes to distinct cell populations within the same fly40. Using this approach, we examine prion-like spreading of mutant Htt by monitoring the redistribution of cytoplasmic wild-type Htt from its normally diffuse, soluble state to an aggregated state, a direct consequence of physical contact with a pre-formed mutant Htt aggregate "seed." Conversion of wild-type Htt by mutant Htt can be confirmed using biochemical or biophysical techniques that report protein-protein interactions, such as fluorescence resonance energy transfer (FRET)9,27,41.
Importantly, we can also access a large number of genetic tools in Drosophila to identify genes and/or pathways that mediate prion-like spread of protein aggregates. We have recently used this approach to unveil a key role for the cell surface scavenger receptor, Draper42,43, in transferring mutant Htt aggregates from neuronal axons to nearby phagocytic glia in the Drosophila central nervous system (CNS)27. Thus, the genetic- and imaging-based approach that we describe here can reveal important basic biological information about a disease-relevant phenomenon in the simple-to-use but powerful model organism, Drosophila.
1. Coupling Gal4- and QF-mediated Htt Transgene Expression in Drosophila
Figure 1. Genetic approach for coupled expression of mutant and wild-type Htt transgenes using the QF-QUAS and Gal4-UAS binary expression systems. In "cell A," an mCherry-tagged mutant Htt protein containing a pathogenic-length polyQ stretch (Q91) is expressed using a QF driver located downstream of a tissue-specific promoter A ("PA"). In "cell B," a YFP-tagged wild-type Htt containing a normal polyQ stretch (Q25) is expressed via a Gal4 driver controlled by tissue-specific promoter B ("PB"). In Figures 2-4, Or67d-QF was used to drive QUAS-HttQ91-mCherry expression in DA1 ORNs, and repo-Gal4 was used to express UAS-HttQ25-YFP in all glia27. Importantly, HttQ91-mCherry is only expressed in QF-expressing cells by virtue of the QUAS sequence placed upstream of the transgene. Similarly, HttQ25-YFP is only expressed via Gal4, which specifically recognizes the UAS. If any overlap in the tissue distribution of the QF and Gal4 drivers is detected, transgenes encoding QS in Gal4-expressing cells and Gal80 in QF-expressing cells can be introduced. Appending fluorescent protein tags onto wild-type and mutant Htt allows for differentiation of the two proteins during imaging and the ability to measure FRET between appropriate donor/acceptor pairs (e.g., CFP/YFP or YFP/mCherry). Please click here to view a larger version of this figure.
2. Micro-dissection and Fixation of Adult Drosophila Brains
Note: This dissection procedure has been modified from a previous publication44, and can be used to prepare brains for imaging direct fluorescence signal from Htt-fluorescent protein fusions. Modifications to the procedure that can be made for immunostaining the brains are discussed in the next section.
3. Modifications to Section 2 for Immunostaining Adult Brains
Note: Use this protocol for imaging non-fluorescent proteins or for fluorescent protein fusions with weak fluorescence.
4. Whole Brain Mounting
5. Imaging and Quantifying Prion-like Transmission of Aggregates
The methods described here produce robust data demonstrating prion-like transfer of Htt protein aggregates from one cell population to another in the intact fly CNS. Conversion of wild-type Htt from diffuse to punctate is observed by direct fluorescence of this YFP fusion protein in recipient glia as a result of HttQ91-mCherry expression in donor ORNs (Figure 2A-C and Figure 4A, B). Accurate reporting of prion-like transfer events between these two cell populations requires careful selection of transgenic flies and Gal4/QF drivers to produce strong expression levels of mutant and wild-type Htt transgenes without any overlap during development or in adulthood. In addition, thoughtful design of the fluorescent protein-Htt fusion transgenes can enable powerful downstream analyses. For example, mutant and wild-type Htt aggregates can be quantified as punctate objects either manually (Figure 2C and Figure 4A) or using image analysis software (Figure 3A, B), can be measured and characterized further as aggregate populations (Figure 3C), can be assessed for co-localization between mutant and wild-type proteins (Figure 4A), and can be analyzed for FRET27 (Figure 4B). These analyses require fusion of mutant and wild-type Htt to fluorescent protein tags with sufficiently separated fluorescence properties, but with enough spectral overlap to enable FRET between donor and acceptor pairs (e.g., CFP/YFP9 or YFP/mCherry27).
Figure 2. Confocal images of prion-like conversion of glial HttQ25-YFP by neuronal HttQ91-mCherry aggregates. (A) Maximum intensity projection of ~ 30 µm of confocal slices showing one antennal lobe from a male fly expressing HttQ91-mCherry (red) in DA1 ORN axons using Or67d-QF and HttQ25-YFP (green) in glia using repo-Gal4. The approximate boundaries of the antennal lobe and DA1 glomerulus, where DA1 ORN axons terminate, are indicated by the dotted and solid lines, respectively. (B) Maximum intensity projection from ~ 20 µm of confocal slices showing a magnified view of the DA1 glomerular region from A. (C) A single 0.35 µm confocal slice showing a single HttQ25-YFP puncta and its associated HttQ91-mCherry signal (indicated by the arrow in each channel). The signal in the red channel was enhanced to visualize co-localization between HttQ25-YFP and HttQ91-mCherry signals. All images were acquired using a 40X 1.4NA oil objective. Scale bars = 10 µm. Please click here to view a larger version of this figure.
Figure 3. Three-dimensional analysis of HttQ91-mCherry aggregates in DA1 ORN axons. (A) A 3D depiction of HttQ91-mCherry aggregates expressed in the DA1 glomerulus via Or67d-QF using the same data shown in Figure 2B. (B) A screenshot showing individual objects or "spots" identified from the raw data in (A) using an image analysis software package. The software identified 56 objects of varying sizes in this channel/image. The spot indicated by the arrowhead in (B) was measured to have a diameter of ~ 1.2 µm. Arrows point to locations where two objects are inaccurately merged into one spot by the software, likely due to close proximity of the individual puncta. To overcome this, different thresholding settings should be tested in the software and/or merged spots should be separated manually if possible. Scale bars = 10 µm. (C) Histogram showing the distribution of diameters measured by the software for the HttQ91-mCherry "spots" shown in (B). Please click here to view a larger version of this figure.
Figure 4. Co-localization and FRET analysis of induced HttQ25-YFP aggregates. (A) A montage of 4 individual 0.35 µm confocal z-slices from a male fly brain expressing HttQ91-mCherry in DA1 ORNs using Or67d-QF and HttQ25-YFP in glia using repo-Gal4. The signals were adjusted so that even small HttQ91-mCherry aggregates are visible and induced HttQ25-YFP aggregates stand out from surrounding diffuse signal. The slices shown are each separated by ~ 1.0 µm (slice number indicated at lower right corner of merged images) so that multiple aggregates can be observed. Arrows indicate HttQ25-YFP puncta that were determined to be in or near focus in that particular z-slice by manually moving through the z-stack. Of the seven HttQ25-YFP puncta indicated here, six have detectably associated HttQ91-mCherry signal (i.e., 86% of the HttQ25-YFP aggregates co-localize with HttQ91-mCherry). Note that the mCherry signal associated with HttQ25-YFP puncta is often weaker than the majority of mCherry-positive puncta in the DA1 glomerulus. Scale bar = 5 µm. (B) A HttQ25-YFP/HttQ91-mCherry-co-localized punctum before (left panels) and after (right panels) mCherry (acceptor) photobleaching. The resulting increase in YFP (donor) fluorescence was used to produce a pixel-by-pixel FRET efficiency (FRETeff) image using the AccPbFRET plug-in for ImageJ46. This particular aggregate has an overall FRETeff of 61%. Scale bar = 1 µm. Please click here to view a larger version of this figure.
As the numbers of patients suffering from neurodegenerative diseases continues to increase, there is an urgent need to increase the understanding of the molecular pathogenesis of these diseases so that better therapies can be developed. Here, we describe methods that allow for monitoring prion-like transmission of pathogenic protein aggregates between different cell types in the model organism, Drosophila melanogaster. We have recently used this methodology to demonstrate prion-like transmission of mutant Htt aggregates in vivo and to identify a phagocytic receptor that mediates spread of these aggregates from neurons to glia27. Our approach exploits several advantages of using Drosophila to study genetic human disease: its short life cycle and vast genetic toolset, which can accelerate discovery of basic biological information that is therapeutically relevant.
The methods we describe here offer two major advantages over other existing animal and cell culture models for prion-like transmission: (1) the aggregating causative agent (e.g., mutant Htt) is produced in a cell residing in an intact tissue, and (2) expression of the normally-folded version of the same protein (e.g., wild-type Htt) in a separate cell population provides a readily accessible "reporter" for prion-like events. We have achieved expression of mutant and wild-type Htt proteins in non-overlapping cell populations within the same organism by using sophisticated genetic tools that are well-established in Drosophila40. Because many different tissue-specific Gal4 and QF drivers are readily available, examining prion-like transfer between essentially any distinct cell types in the fly body is feasible.
A critical component of the approach is achieving segregated expression of mutant and wild-type Htt proteins in different cell populations within the same animal. Any expression overlap needs to be eliminated so that wild-type Htt aggregation in recipient cells accurately reports cytoplasmic penetration of prion-like aggregates originating in donor cells9,12,27,41. This can be accomplished by introducing additional genetic tools (e.g., Gal80 and QS repressors40) to alleviate this issue. Once the ideal genotype is designed and selected, a systematic method for quantifying puncta must be established. This will largely depend on the number of cells that are labeled, the number of aggregates that appear, and the signal-to-noise ratio of the sample. Criteria such as co-localization and/or positive FRET can be used for analyzing the data, as we have described here in Figure 4. However, restricting selection of wild-type Htt aggregates based on these features may lead to underestimation of prion-like transfer events, since some mutant Htt aggregate seeds might fall below the limit of detection of the confocal microscope.
The in vivo approach described here is not exclusive for prion-like behavior of aggregates associated with HD or even other polyQ disorders. Transgenic flies can be developed to examine prion-like spreading of alpha-synuclein in PD, tau in AD, and SOD1 or TDP-43 in ALS using the same experimental paradigm. For each of these proteins, an aggregation-prone mutant should be expressed in donor cells, and a soluble version of the same protein that only aggregates when nucleated should be expressed in recipient cells. This experimental paradigm can also be useful for investigating the emerging idea that pathogenic proteins associated with different diseases might interact through a cross-seeding mechanism47. Finally, the myriad genetic tools available in Drosophila can be applied to investigate and identify molecular mechanism(s) underlying cytoplasm-to-cytoplasm spreading of pathogenic protein aggregates associated with these fatal diseases.
The authors have nothing to disclose.
We thank members of the Kopito, Luo, and Pearce labs for many helpful discussions during development of these methods. We also thank Brian Temsamrit for critical reading of this manuscript. This work was supported by funds from University of the Sciences and the W.W. Smith Charitable Trusts.
Phosphate buffered saline (PBS), 10X, pH 7.4 | ThermoFisher Scientific | AM9625 | Dilute to 1X |
Triton X-100 | Sigma-Aldrich | T9284-1L | |
Kimwipes | Thomas Scientific | 2904F24 | |
20% paraformaldehyde (PFA) | Electron Microscopy Sciences | 15713-S | |
Normal Goat Serum (NGS), filtered | Lampire Biological Laboratories | 7332500 | Aliquot and freeze upon receipt |
Chicken anti-GFP | Aves Labs | GFP-1020 | Use at 1:500 dilution |
Rabbit anti-DsRed | Clontech | 632496 | Use at 1:2000 dilution; can recognize DsRed-based fluorescent proteins (e.g. mCherry, mStrawberry, tdTomato, etc.) |
Mouse anti-Bruchpilot | Developmental Studies Hybridoma Bank | nc82 | Use at 1:100 dilution; will label active pre-synaptic structures thoughout the fly brain |
FITC anti-chicken | ThermoFisher Scientific | SA1-7200 | Use at 1:250 dilution |
Alexa Fluor 568 anti-rabbit | Life Technologies | A11011 | Use at 1:250 dilution |
Alexa Fluor 647 anti-mouse antibody | Life Technologies | A21235 | Use at 1:250 dilution |
Slowfade Gold Antifade Reagent | Life Technologies | S36936 | |
Microscope Slides (25 x 75 x 1.0 mm) | Fisher Scientific | 12-550-143 | |
Cover Glass (22 x 22 mm) | Globe Scientific | 1404-15 | |
Dumont Biology Grade Forceps, Style 3 | Ted Pella | 503 | use in non-dominant hand |
Dumont Biology Grade Forceps, Style 5 | Ted Pella | 505 | use in dominant hand |
LAS X image analysis software | Leica | ||
Imaris image analysis software | Bitplane |